Mutagenic potential of temozolomide in bone marrow cells in vivo

被引：34

作者：

Geiger, H ^{[1
]}

Schleimer, D ^{[1
]}

Nattamai, KJ ^{[1
]}

Dannenmann, SR ^{[1
]}

Davies, SM ^{[1
]}

Weiss, BD ^{[1
]}

机构：

[1] Childrens Hosp, Med Ctr, Dept Pediat, Div Expt Hematol, Cincinnati, OH 45229 USA

来源：

BLOOD | 2006年 / 107卷 / 07期

关键词：

D O I：

10.1182/blood-2005-09-3649

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

引用

收藏

页码：3010 / 3011

页数：2

相关论文

共 9 条

[1]

Bodell WJ, 2003, CANCER EPIDEM BIOMAR, V12, P545

[2]

DEVITA S, 2005, ANN HEMATOL

[3]

GERSON SL, 1987, CANCER RES, V47, P89

[4]

Myeloid malignancies induced by alkylating agents in Nf1 mice [J].

Mahgoub, N ;

Taylor, BR ;

Le Beau, MM ;

Gratiot, M ;

Carlson, KM ;

Atwater, SK ;

Jacks, T ;

Shannon, KM .

BLOOD, 1999, 93 (11) :3617-3623

[5]

Evaluation of temozolomide in patients with myelodysplastic syndrome [J].

Seiter, K ;

Liu, DL ;

Siddiqui, AD ;

Lerner, R ;

Nelson, J ;

Ahmed, T .

LEUKEMIA & LYMPHOMA, 2004, 45 (06) :1209-1214

[6]

Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series [J].

Smith, SM ;

Le Beau, MM ;

Huo, DZ ;

Karrison, T ;

Sobecks, RM ;

Anastasi, J ;

Vardiman, JW ;

Rowley, JD ;

Larson, RA .

BLOOD, 2003, 102 (01) :43-52

[7]

Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma [J].

Su, YW ;

Chang, MC ;

Chiang, MF ;

Hsieh, RK .

JOURNAL OF NEURO-ONCOLOGY, 2005, 71 (03) :315-318

[8]

Vijg J, 1997, MECH AGEING DEV, V99, P257

[9]

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse [J].

Yung, WKA ;

Albright, RE ;

Olson, J ;

Fredericks, R ;

Fink, K ;

Prados, MD ;

Brada, M ;

Spence, A ;

Hohl, RJ ;

Shapiro, W ;

Glantz, M ;

Greenberg, H ;

Selker, RG ;

Vick, NA ;

Rampling, R ;

Friedman, H ;

Phillips, P ;

Bruner, J ;

Yue, N ;

Osoba, D ;

Zaknoen, S ;

Levin, VA .

BRITISH JOURNAL OF CANCER, 2000, 83 (05) :588-593